From Drug Discovery & Development : Positive Study Results for Schizophrenia Drug Drug Discovery & Development December 05, 2011 "EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia." Read the full report
News about our knowledge of the brain and behavior
from Anthony Risser, Ph.D.